Pay in 4 interest-free payments of $7.30 Learn more
Ships within 48 hours · Estimated delivery Sep 4 - Sep 9
To summarize, on one hand the modest upwards trajectory of the obese and diabetic population provides a fertile ground for Pharma companies to sell more for the years to come, however, downside risks remain, including: pricing, compounders and overall competition, which will make it hard for companies like Novo and Lilly to maintain their growth
Brands with smaller revenue but deeper clinical credibility - Thorne, Seed - out-ranked AG1 in head-to-head comparison queries
Keller J, Ringseis R, Koc A, Lukas I, Kluge H, Eder K
It is also the first-ever FDA-approved medication specifically for OSA, a condition that until now has primarily relied on mechanical interventions such as CPAP machines and oral appliances
doi:10.1093/cvr/cvq271 152
